Scarica l'app Stockscreener
9.05
0.44%
0.04
Dopo l'orario di chiusura:
9.13
0.08
+0.88%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$9.01
Aprire:
$9.16
Volume 24 ore:
3.73M
Relative Volume:
0.81
Capitalizzazione di mercato:
$2.35B
Reddito:
$6.29B
Utile/perdita netta:
$750.00M
Rapporto P/E:
3.1424
EPS:
2.88
Flusso di cassa netto:
$586.00M
1 W Prestazione:
+7.74%
1M Prestazione:
-8.95%
6M Prestazione:
-38.44%
1 anno Prestazione:
-53.49%
Intervallo 1D:
$8.985
$9.26
Intervallo di 1 settimana:
$8.315
$9.36
Portata 52W:
$8.01
$23.10
Organon Co Stock (OGN) Company Profile
Nome
Organon Co
Settore
Industria
Telefono
551-430-6000
Indirizzo
30 HUDSON STREET, JERSEY CITY
Confronta OGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.05 | 2.40B | 6.29B | 750.00M | 586.00M | 2.88 |
|
LLY
Lilly Eli Co
|
639.43 | 560.87B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
172.78 | 417.44B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.64 | 349.87B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
119.31 | 226.19B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.30 | 201.55B | 63.62B | 16.41B | 14.72B | 6.49 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-09-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-11-03 | Downgrade | Goldman | Buy → Neutral |
| 2023-09-21 | Iniziato | Barclays | Overweight |
| 2023-03-16 | Iniziato | Raymond James | Outperform |
| 2022-10-14 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Iniziato | Piper Sandler | Neutral |
| 2021-09-01 | Iniziato | BofA Securities | Buy |
| 2021-07-22 | Iniziato | Citigroup | Buy |
| 2021-06-15 | Iniziato | JP Morgan | Neutral |
| 2021-06-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-06-10 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Organon Co Borsa (OGN) Ultime notizie
Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - uk.finance.yahoo.com
Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World
Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest
Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - sg.finance.yahoo.com
Organon & Co. (OGN) Reports Q2 2025 Results - MSN
Organon Q2 Preview: What to expect? - MSN
Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail
Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail
Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com
Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN
Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha
Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail
Organon & Co. SEC 10-Q Report - TradingView
Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace
Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada
Organon: Q2 Earnings Snapshot - Norwalk Hour
Organon raises 2025 revenue guidance by $100M amid Vtama ramp and debt reduction focus - MSN
Organon & Co To Go Ex-Dividend On August 15th, 2025 With 0.02 USD Dividend Per Share - 富途牛牛
Organon reports Q2 adjusted EPS $1.00, consensus 94c - TipRanks
Organon raises FY25 revenue view to $6.28B-$6.38B from $6.13B-$6.33B - TipRanks
OGN Shares Plunge: Lawsuit Drives Market Shock - StocksToTrade
Organon & Co. 2025 Q2ResultsEarnings Call Presentation (NYSE:OGN) - Seeking Alpha
Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile - Investing.com
Organon Becomes Oversold - Nasdaq
Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Organon & Co. Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Organon surpasses expectations with $1.59B revenue in Q2 2025 - grafa.com
Organon's Strategic Path to Financial Stability and Dividend Resumption - AInvest
Organon Q2 2025 slides: Revenue guidance raised amid Women’s Health strength - Investing.com Australia
Organon (OGN) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN
Organon Q2 Adjusted Earnings, Revenue Fall, Beat Estimates; 2025 Revenue Guidance Raised - MarketScreener
Organon stock jumps after Q2 revenue beat (OGN:NYSE) - Seeking Alpha
Organon (NYSE:OGN) Surprises With Q2 Sales, Stock Soars - Yahoo Finance
Organon shares surge over 8% as Q2 earnings top estimates, raises revenue outlook By Investing.com - Investing.com South Africa
Organon shares surge over 8% as Q2 earnings top estimates, raises revenue outlook - Investing.com India
Organon Co earnings beat by $0.06, revenue topped estimates - Investing.com Australia
Earnings Snapshot: Organon new revenue outlook beats estimates after strong Q2 (OGN:NYSE) - Seeking Alpha
Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 (NYSE:OGN) - Seeking Alpha
Organon beats Q2 revenue expectations, raises FY guidance - MarketScreener
Earnings Flash (OGN) Organon & Co. Reports Q2 Revenue $1.59B, vs. FactSet Est of $1.55B - MarketScreener
Organon Earnings: What To Look For From OGN - Yahoo Finance
Organon & Co. (OGN) Expected to Announce Earnings on Tuesday - Defense World
Insights Into Organon (OGN) Q2: Wall Street Projections for Key Metrics - Yahoo Finance
Organon (OGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
OGN’s Market Whiplash: -54.75% YTD Decline, 3.72% Rise in 30 Days - investchronicle.com
Organon Co Azioni (OGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Organon Co Azioni (OGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
| Ali Kevin | Chief Executive Officer |
May 05 '25 |
Buy |
8.80 |
34,000 |
299,370 |
282,731 |
| Falcione Aaron | Chief Human Resources Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,732 |
0 |
59,237 |
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '25 |
Option Exercise |
0.00 |
8,865 |
0 |
20,552 |
1.78%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):